GMRE - NYSE
Global Medical REIT Inc.
$35.74
-1.2%Global Medical REIT Inc. is net-lease medical office REIT that acquires purpose-built specialized healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share.
At a Glance
Live SnapshotGlobal Medical REIT Inc. Management Team
Mr. Jeffrey M. Busch J.D.
Chairman, President & Chief Executive Officer
Compensation
$734,179
Mr. Robert J. Kiernan CPA
Chief Financial Officer & Treasurer
Compensation
$595,312
Mr. Alfonzo Leon
Chief Investment Officer
Compensation
$558,105
Ms. Danica C. Holley
Chief Operating Officer
Compensation
$451,953
Mr. Jamie A. Barber
General Counsel & Corporate Secretary
Compensation
$403,281
Mr. Stephen C. Swett
Investor Relations Executive
Global Medical REIT Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.57M and sold $861K worth of GMRE shares, resulting in $709K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
18.9K
613.99K
0
0.00
+614K
+$614K
9-12 Months
146.0K
956.40K
130.0K
861.07K
+95K
+$95K
Top Buyers
Decker Mark Okey Jr
Director, Officer: Ceo And President
$1.46M
Kiernan Robert J
Officer: Cfo And Treasurer
$96K
Cypher Matthew
Director
$10K
Top Sellers
Barber Jamie Allen
Officer: General Counsel And Secretary
$861K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $709K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Insider Participation
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
SEC Filings
GMRE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | March 31, 2025 | May 14, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 01, 2024 | May 15, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 31, 2023 | March 31, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 31, 2022 | May 11, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 16, 2021 | May 26, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | July 24, 2020 | September 02, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 18, 2019 | May 29, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 19, 2018 | May 30, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 07, 2017 | May 18, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.